Altimmune warns 6 million in the U.S. face alcohol associated liver disease with no approved therapies

Altimmune warns 6 million in the U.S. face alcohol associated liver disease with no approved therapies
Altimmune: U.S. liver disease gap

Altimmune reports that 6 million adults in the U.S. are currently diagnosed with alcohol associated liver disease, yet no approved therapies exist for this condition.

The company states its commitment to addressing this critical gap in care by advancing research efforts targeting liver disease. The lack of approved treatments underscores the urgent need for innovative approaches and increased attention from the medical community and regulators. Details about Altimmune's specific research initiatives were not disclosed in the announcement.

Altimmune recently participated in the Jefferies Healthcare Conference in New York, where company leaders engaged in a fireside chat on June 4. The firm also marked Global Fatty Liver Day by advancing innovation in treatments for metabolic dysfunction-associated steatohepatitis and serious liver disease. Details from these initiatives were reported in coverage of the Jefferies conference and the Fatty Liver Day announcement.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.